Brief: Auris Medical Says Phase 2 Trial With Intranasal Betahistine For Treatment Of Acute Vertigo Progressing Towards Interim Analysis

Altamira Therapeutics

16/04/2020 12:26

April 16 (Reuters) - Auris Medical Holding Ltd  EARS.O :
    * AURIS MEDICAL PROVIDES BUSINESS UPDATE AND REPORTS SECOND
HALF
AND FULL YEAR 2019 FINANCIAL RESULTS
    * AURIS MEDICAL - PHASE 2 TRIAL WITH INTRANASAL BETAHISTINE
FOR
TREATMENT OF ACUTE VERTIGO PROGRESSING TOWARDS INTERIM ANALYSIS
    * AURIS MEDICAL HOLDING LTD - EXPECTS ITS TOTAL CASH NEED IN
2020
TO BE IN RANGE OF CHF 7.5 TO 10.0 MILLION
    * AURIS MEDICAL - PHASE 1B TRIAL WITH INTRANASAL BETAHISTINE
FOR
PREVENTION OF ANTIPSYCHOTIC-INDUCED WEIGHT GAIN PROGRESSING
TOWARDS FINAL READ-OUT
    * AURIS MEDICAL - EXPECT TO RECEIVE TOP-LINE DATA FROM
COMPLETED
AM-201 TRIAL IN EARLY MAY AND INTERIM DATA FROM AM-125 TRIAL IN
Q3

Source text for Eikon:  ID:nGNX5MgjdJ 
Further company coverage:  EARS.O 

 (Reuters.Briefs@thomsonreuters.com)